Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma

This study has been terminated.
(Slow accrual)
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Comprehensive Cancer Center of Wake Forest University
ClinicalTrials.gov Identifier:
NCT01103375
First received: April 13, 2010
Last updated: July 27, 2015
Last verified: July 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: March 2013
  Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)